Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

Giani M, Mastrangelo A, Villa R, Turolo S, Marra G, Tirelli AS, Hopfer H, Edefonti A.

Pediatr Nephrol. 2013 Sep;28(9):1837-42. doi: 10.1007/s00467-013-2490-z. Epub 2013 Jun 11.

PMID:
23748277
2.
3.

The effect of aldosterone blockade in patients with Alport syndrome.

Kaito H, Nozu K, Iijima K, Nakanishi K, Yoshiya K, Kanda K, Przybyslaw Krol R, Yoshikawa N, Matsuo M.

Pediatr Nephrol. 2006 Dec;21(12):1824-9. Epub 2006 Oct 13.

PMID:
17039334
4.

Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.

Guney I, Selcuk NY, Altintepe L, Atalay H, Başarali MK, Büyükbaş S.

Ren Fail. 2009;31(9):779-84. doi: 10.3109/08860220903150312.

PMID:
19925284
5.

Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion.

Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H.

BMC Nephrol. 2002 Feb 14;3:2.

6.

Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.

Kim HY, Bae EH, Ma SK, Kim SW.

Kidney Blood Press Res. 2014;39(6):573-80. doi: 10.1159/000368470. Epub 2014 Dec 15.

7.

Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome.

Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, Lam C.

Pediatr Nephrol. 2013 May;28(5):737-43. doi: 10.1007/s00467-012-2372-9. Epub 2012 Dec 4.

PMID:
23207876
8.

Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.

Morales E, Gutiérrez E, Caro J, Sevillano A, Rojas-Rivera J, Praga M.

Nefrologia. 2015 Nov-Dec;35(6):554-61. doi: 10.1016/j.nefro.2015.09.008. Epub 2015 Oct 28.

9.

Aldosterone antagonists for preventing the progression of chronic kidney disease.

Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.

Cochrane Database Syst Rev. 2014 Apr 29;(4):CD007004. doi: 10.1002/14651858.CD007004.pub3. Review.

PMID:
24782282
10.

Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.

Agarwal R, Siva S, Dunn SR, Sharma K.

Am J Kidney Dis. 2002 Mar;39(3):486-92.

PMID:
11877567
12.

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.

Am J Kidney Dis. 2008 Sep;52(3):486-93. doi: 10.1053/j.ajkd.2008.02.297. Epub 2008 Apr 18.

PMID:
18423812
13.

Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats.

Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR.

Kidney Int. 2006 Jul;70(1):111-20. Epub 2006 May 24.

14.

Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.

Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.

Nephrol Dial Transplant. 2013 Nov;28(11):2823-33. doi: 10.1093/ndt/gft281. Epub 2013 Sep 5.

PMID:
24009294
16.

Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.

Zhang Y, Wang F, Ding J, Zhang H, Liu X, Wang S, Xiao H, Yao Y, Liu J, Zhong X, Guan N, Su B, Wu G, Yu L.

Pediatr Nephrol. 2016 Jan;31(1):67-72. doi: 10.1007/s00467-015-3184-5. Epub 2015 Aug 7.

PMID:
26248473
17.

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.

Bianchi S, Bigazzi R, Campese VM.

Kidney Int. 2006 Dec;70(12):2116-23. Epub 2006 Oct 11.

18.

Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.

Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.

Nephrol Dial Transplant. 2009 Jan;24(1):73-84. doi: 10.1093/ndt/gfn448. Epub 2008 Aug 5.

PMID:
18682491
19.

Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.

Erman A, Veksler S, Gafter U, Boner G, Wittenberg C, van Dijk DJ.

J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):146-51.

PMID:
15526251
20.

[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].

Morales E, Huerta A, Gutiérrez E, Gutiérrez Solís E, Segura J, Praga M.

Nefrologia. 2009;29(5):421-9. doi: 10.3265/Nefrologia.2009.29.5.5448.en.full. Spanish.

Supplemental Content

Support Center